By Timothy S. Donahue
Top Takeaways:
- Second Revocation: The European Patent Office has revoked another Philip Morris nicotine pouch patent following a challenge by BAT.
- Procedural Exit: Philip Morris withdrew its approval of the patent text at the end of oral proceedings, preventing a final substantive ruling.
- Patent Battles Continue: Related divisional applications remain subject to separate proceedings, leaving broader IP disputes unresolved.
Philip Morris is two patents down in its pouch fight with BAT.
The European Patent Office (EPO) has revoked a second nicotine pouch patent held by Philip Morris Products S.A., a subsidiary of Philip Morris International (PMI), following a challenge by British American Tobacco (BAT) subsidiary Nicoventures Trading Limited.
The decision, published November 17 and dated October 13, concerns European patent EP 3773494, titled “Nicotine Pouch Composition and Pouch Comprising Such.” The patent covers a formulation incorporating free-base nicotine, ion-exchange resin, and a water content of at least 15%.
The ruling overturns a December 2024 decision by the EPO’s Opposition Division that allowed the patent to be maintained in amended form.
Philip Morris initially sought dismissal of the appeal and submitted 15 alternative requests to preserve its patent protection should its principal request fail.
However, at the conclusion of the oral proceedings, Philip Morris withdrew its approval of the patent text and all pending claim requests, effectively leaving the EPO without an approved version of the patent on which to rule.
Nicoventures objected, arguing that the late withdrawal amounted to an abuse of procedure because it allowed Philip Morris to avoid a fully reasoned decision. The BAT subsidiary also pointed to a pending divisional application covering similar technology and requested a different allocation of legal costs.
The EPO rejected those objections, explaining that Article 113(2) of the European Patent Convention allows patent holders to withdraw their approval of patent texts at any stage of the proceedings.
Although the board acknowledged that its preliminary opinion had favored Nicoventures, it concluded that Philip Morris’ withdrawal did not constitute procedural abuse or justify reallocating costs.
The board’s order was straightforward: “The patent is revoked.”
The decision follows the September 24 revocation of another Philip Morris nicotine pouch patent, EP 3809884, following a challenge by another BAT subsidiary. That patent concerned the distribution of nicotine between a pouch’s internal composition and its outer membrane.
Both patents share a June 7, 2019, priority date, and both revocations resulted from Philip Morris withdrawing its approval of the patent texts during appeal proceedings.
The distinction is significant. Neither revocation resulted in a final substantive determination that the inventions lacked novelty or inventive step, two fundamental requirements for patent protection.
In the latest case, the board explained that it was “precluded from any substantive examination” once Philip Morris withdrew its approval.
The decisions come amid intensifying competition between the world’s largest tobacco companies in the rapidly growing oral nicotine category, where PMI’s Zyn and BAT’s Velo are competing for market share.
Patent protection covering nicotine formulations, moisture content, delivery mechanisms, and pouch construction represents an important competitive consideration for manufacturers seeking to differentiate their products.
While the two revocations remove specific European patent protections, they do not automatically invalidate related patents or divisional applications, which remain subject to separate examination and opposition proceedings.




